Results 231 to 240 of about 78,266 (303)

Botulinum Toxin for First Bite Syndrome: A Symptom‐Guided “Follow‐The‐Pain” Injection Strategy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background To evaluate botulinum toxin type A (BoNT‐A) for First Bite Syndrome (FBS) and assess a symptom‐guided “Follow‐the‐Pain” (FTP) injection strategy in patients with incomplete response to standard treatment. Methods Consecutive patients with postoperative FBS were treated with ultrasound‐guided intraparotid BoNT‐A injection.
Rosario Marchese‐Ragona   +5 more
wiley   +1 more source

Editorial: Pain management in spine surgery. [PDF]

open access: yesFront Surg
Yang Y, Han F, Xiang H, Tu J, Yang S.
europepmc   +1 more source

Pain Management Strategies in Reverse Total Shoulder Arthroplasty. [PDF]

open access: yesCurr Rev Musculoskelet Med
David WB   +3 more
europepmc   +1 more source

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

open access: yesIbrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source

Cost‐effectiveness of a randomized controlled trial comparing low‐dose aspirin to placebo for the prevention of recurrent preterm birth

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 399-407, April 2025.
Abstract To assess the cost‐effectiveness of low‐dose aspirin compared to placebo for the prevention of recurrent preterm birth from a healthcare perspective. This was a cost‐effectiveness analysis alongside a multicenter, randomized, double‐blinded, placebo‐controlled trial.
Anadeijda J. E. M. C. Landman   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy